A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract

Clicks: 125
ID: 270003
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #627 of 1,084 articles by views in clinical infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Presatovir treatment was safe but did not improve viral or clinical outcomes in hematopoietic-cell transplant recipients with respiratory syncytial virus lower
Reference Key
m2020clinicala Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marty, Francisco M;Chemaly, Roy F;Mullane, Kathleen M;Lee, Dong-Gun;Hirsch, Hans H;Small, Catherine B;Bergeron, Anne;Shoham, Shmuel;Ljungman, Per;Waghmare, Alpana;Blanchard, Elodie;Kim, Yae-Jean;McKevitt, Matt;Porter, Danielle P;Jordan, Robert;Guo, Ying;German, Polina;Boeckh, Michael;Watkins, Timothy R;Chien, Jason W;Dadwal, Sanjeet S;
Journal clinical infectious diseases
Year 2020
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.